Lithium: Clinical Uses and Pharmacokinetics

Slides:



Advertisements
Similar presentations
Mirtazapine Flavio Guzmán, MD. Mirtazapine- Overview NaSSA (Noradrenergic and specific serotonergic antidepressant) H1 antagonist Sedation and weight.
Advertisements

2003 August Dar Al-Ajaza Al-Islamia Hospital in Beirut1 Bipolar Disorder An Update Presented by Dr Ismail Habli Moderator: Dr Elio Sassine.
Treatment of Acute Mania in Pediatric Bipolar Disorder Assessing the Evidence Stewart S. Newman MD Senior Child Fellow.
Réunion Ambulatoires SAS,  Similarly, a statistically significant MADRS reduction over time was found (F=156.2, p 800 mg/day) and low (
2007. Statistics  2-4 new cases per 100,000/year  1 in 200 people will have an episode of hypomania  Peak age of onset yrs  May have had a previous.
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
Bipolar Disorders.
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 33 Drugs for Bipolar Disorder.
Nasa Valentine, MD Wael Hamade, MD Than Luu, MD
New treatment options for use in bipolar mania Dr C Verster Dept Psychiatry Uuniversity of Stellenbosch.
Psychopharmacology – A brief introduction. Objectives Review general categories of psychiatric disorders Review general categories of psychiatric disorders.
Bipolar I Disorder Treatment. Therapeutic Goals Relief of immediate symptoms Improvement of patient’s well-being Elimination of stressors Combined pharmacotherapy.
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
Lyn Billington June 2006 Treatment of Attention Deficit/Hyperactivity Disorder Lyn Billington Deputy Pharmacy Manager Latrobe Regional Hospital.
Psychotherapies in Treatment of Depression Copyright © World Psychiatric Association.
Treatment Resistant Pediatric BD Elham Shirazi M.D. Board of General Psychiatry Board of Child & Adolescent Psychiatry.
If I’m on fire they dance around it and cook marshmallows. And if I’m ice they simply skate on me in little ballet costumes Anne Sexton was a poet born.
Chapter 18 Bipolar Mood Disorder. Definition 1.Bipolar I disorder # disorder in which at least one manic or mixed episode has occurred # commonly accompanied.
BIPOLAR DISORDER, DR GIAN LIPPI CONSULTANT PSYCHIATRIST UNIVERSITY OF PRETORIA & WESKOPPIES HOSPITAL FORENSIC UNIT MANAGEMENT GUIDELINES.
Long-term Efficacy for Psychiatric Drugs Frederick K. Goodwin, MD George Washington University Medical Center Frederick K. Goodwin, MD George Washington.
Drugs for Bipolar Disorder. Bipolar Disorder  Formerly known as manic-depressive illness  Afflicts an estimated 3.7% of the adult population  Mainstays.
Bipolar Disorder. What is it? Definition: “previously known as manic depression - is a condition that affects your moods, which can swing from one extreme.
โดย เภสัชกรณัฐวุฒิ จรีบุญ สมโภช. OAB affects 33 million people in the United States (17% of American adults) more common in women and in older people.
Depression in chronic kidney disease 신장내과 R4 정우진 Mini topic.
Module 3 Use of antipsychotics for unipolar depression
Module 3 Indications for Antipsychotics Bipolar Disorder
Lithium Practical Prescribing
Module 3 Indications Antipsychotics for Schizophrenia
Presentation on Bipolar Disorder
for the Psychiatry Clerkship
Is it a potential indicator to initiate HAART?
Drugs for Bipolar Disorder
Introduction to bipolar disorder
Other drugs used in the treatment of bipolar disorder
Bipolar Depression Pharmacotherapy: Part 1
Bipolar Disorder: Latest Clinical Update
Recently approved antipsychotics
הרצאה יורם יובל המחלקה לפסיכולוגיה אוניברסיטת בר-אילן
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Tricyclic and Tetracyclic Antidepressants Pharmacology and Indications
Lithium Use During Pregnancy
Sertraline In this section we’ll discuss the most relevant aspects of sertraline.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Valproate MOA and Clinical Uses
Obsessive-Compulsive Disorder: Pharmacotherapy
Lurasidone Flavio Guzmán, MD.
Low risk of sexual dysfunction versus placebo
Insomnia pharmacotherapy: Off-label antipsychotics
Antidepressants for Bipolar Depression: Answering Clinical Questions
Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD.
Prescribing lithium safely: side effects
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Generalized Anxiety Disorder: Clinical Features and Diagnosis
Use of Mood Stabilizers and SGAs During Pregnancy
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Venlafaxine and Desvenlafaxine
Paroxetine Flavio Guzmán, MD.
Fluvoxamine.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
The Challenges of Bipolar Disorders
Tricyclic and Tetracyclic Antidepressants Adverse Effects and Pharmacokinetics In this presentation we discuss adverse effects and pharmacokinetics of.
Obsessive-Compulsive Disorder: Pharmacotherapy
Low risk of sexual dysfunction versus placebo
Module 3 Use of antipsychotics for unipolar depression
PHARMACOTHERAPY - I PHCY 310
Module 3 Indications for Antipsychotic Drugs
Risperidone – Binding Profile
Module 3 Indications for Antipsychotics Bipolar Disorder
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Presentation transcript:

Lithium: Clinical Uses and Pharmacokinetics Flavio Guzman, MD

Indications

Lithium indications FDA-approved: Evidence of effectiveness: Bipolar disorder: manic episodes Bipolar disorder: maintenance treatment Evidence of effectiveness: Bipolar depression Unipolar depression (as adjunctive)

Lithium in mania Pros: More efficacious than placebo FDA-approved for mania Lithium monotherapy: first line option Malhi, G. S., Tanious, M., Das, P., & Berk, M. (2012). The science and practice of lithium therapy. Australian and New Zealand journal of psychiatry,46(3), 192-211.

Lithium in mania Cons: Mixed mania: poor response Relatively slow onset of action Clinical improvement usually seen after 6- 10 days of treatment Malhi, G. S., Tanious, M., Das, P., & Berk, M. (2012). The science and practice of lithium therapy. Australian and New Zealand journal of psychiatry,46(3), 192-211.

Lithium in mania Lithium is often used in combination with an antipsychotic or benzodiazepine Lithium + AP: better in combination than monotherapy of either agent Malhi, G. S., Tanious, M., Das, P., & Berk, M. (2012). The science and practice of lithium therapy. Australian and New Zealand journal of psychiatry,46(3), 192-211.

Lithium in bipolar depression Evidence: small RCTs 6-8 weeks to take effect Clinical guidelines (APA, NICE): Lithium monotherapy: recommended first line Consider adding: SGA Antidepressant Malhi, G. S., Tanious, M., Das, P., & Berk, M. (2012). The science and practice of lithium therapy. Australian and New Zealand journal of psychiatry,46(3), 192-211.

Lithium as maintenance treatment Effective in prophylaxis of: Manic episodes Depressive episodes Effective in prophylaxis of: Suicidal behavior Malhi, G. S., Tanious, M., Das, P., & Berk, M. (2012). The science and practice of lithium therapy. Australian and New Zealand journal of psychiatry,46(3), 192-211.

Lithium as maintenance treatment Effect in preventing mania is more pronounced than for depression Abrupt cessation: Recurrence of symptoms Taper lithium slowly (monthly 300 mg) decrements Geddes, J. R.,et al (2004). Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry, 161(2), 217-222. Malhi, G. S., Tanious, M., Das, P., & Berk, M. (2012). The science and practice of lithium therapy. Australian and New Zealand journal of psychiatry,46(3), 192-211.

Lithium as maintenance treatment Patients with rapid cycling generally do less well than patient with less frequent episodes Malhi, G. S., Tanious, M., Das, P., & Berk, M. (2012). The science and practice of lithium therapy. Australian and New Zealand journal of psychiatry,46(3), 192-211.

Lithium for bipolar disorder: summary Efficacious for: Mania Bipolar depression Prophylaxis (maintenance) Reduces suicidal behavior

Lithium for unipolar depression AD AD + Lithium Lithium augmentation: first line for treatment-resistant depression Depression not responding to AD Gitlin, M. Unipolar depression in adults: Treatment with lithium. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed August 2014)

Lithium for unipolar depression AD AD + Lithium Most trials involved tricyclics Further research needed on the role of role of lithium in combination with other antidepressants Depression not responding to AD Gitlin, M. Unipolar depression in adults: Treatment with lithium. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed August 2014)

Lithium for unipolar depression AD AD + Lithium Limited data suggests lithium is comparable to T3 or a second antidepressant Depression not responding to AD Gitlin, M. Unipolar depression in adults: Treatment with lithium. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed August 2014)

Lithium for unipolar depression AD AD + Lithium Lithium augmentation may reduce the risk of completed suicide in patients with unipolar depression Gitlin, M. Unipolar depression in adults: Treatment with lithium. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed August 2014)

Lithium for aggression Effective for aggressive behavior Mental retardation Prison populations Schatzberg, AF, Nemeroff CB. Essentials of Clinical Psychopharmacology 3rd ed.American Psychiatric Publishing, 2013

Lithium for schizoaffective disorder Not approved by the FDA Of value in combination with antipsychotics Useful when affective component is prominent

Pharmacokinetics

Lithium Pharmacokinetics Absorbed from the GI tract Peak plasma concentration 1-2 hours with standard preparations 4 – 5 hours with slow and controlled release formulations No metabolites No protein binding Malhi, G. S., Tanious, M., Das, P., & Berk, M. (2012). The science and practice of lithium therapy. Australian and New Zealand journal of psychiatry,46(3), 192-211.

Lithium Pharmacokinetics Excreted almost entirely by the kidneys Assess renal function Elimination half-life: 18-24 hours Sensitive to glomerular filtration rate Steady state concentrations achieved within 4-5 days Malhi, G. S., Tanious, M., Das, P., & Berk, M. (2012). The science and practice of lithium therapy. Australian and New Zealand journal of psychiatry,46(3), 192-211.

End of presentation